GSK buying Canada's ID Biomedical for $1.4 billion

09/8/2005 | Bloomberg

In a move to acquire a larger share of the flu vaccine market, GlaxoSmithKline is buying Canada's ID Biomedical in a $1.4 billion deal. GSK's Fluarix flu shot was approved by the U.S. FDA Aug. 31, but the company is expected to produce only 8 million doses this year, and one analyst suggests "capacity issues are what's driving" the move to buy the Canadian biotech firm.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ